RT Journal Article
SR Electronic
T1 Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP 61
DO 10.1186/s40425-018-0351-9
VO 6
IS 1
A1 Nayak-Kapoor, Asha
A1 Hao, Zhonglin
A1 Sadek, Ramses
A1 Dobbins, Robin
A1 Marshall, Lisa
A1 Vahanian, Nicholas N.
A1 Jay Ramsey, W.
A1 Kennedy, Eugene
A1 Mautino, Mario R.
A1 Link, Charles J.
A1 Lin, Ray S.
A1 Royer-Joo, Stephanie
A1 Liang, Xiaorong
A1 Salphati, Laurent
A1 Morrissey, Kari M.
A1 Mahrus, Sami
A1 McCall, Bruce
A1 Pirzkall, Andrea
A1 Munn, David H.
A1 Janik, John E.
A1 Khleif, Samir N.
YR 2018
UL http://jitc.bmj.com/content/6/1/61.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.